ImmuDyne (OTCQB:IMMD), a leader in the development and marketing of OTC health and wellness products addressing large unmet needs, today announced the signing of a definitive agreement with Pilaris Laboratories, LLC (“Pilaris”), for a sole and exclusive worldwide license to commercialize the patented PilarisMax line of hair loss products.
As ImmuDyne previously stated, Pilaris was founded by two prominent dermatologists, Steven D. Shapiro M.D. and Michael T. Borenstein M.D. Ph.D. after 5 years of clinical research on topical dihydrotestosterone (DHT) inhibitors. Dr. Shapiro has over 20 years of clinical experience with treating hair loss and hair transplant procedures. Dr. Borenstein holds a Ph.D. in Pharmacology and has a background in scientific research in addition to over 12 years of clinical dermatology practice.